Psychedelics in Functional Medicine: A New Frontier for Mental Health

March 13, 2025

At the intersection of ancient wisdom and modern science, psychedelics like ketamine, MDMA, psilocybin, and DMT are emerging as powerful tools in the treatment of mental health conditions. Once relegated to counterculture or ceremonial use, these substances are now being rigorously studied for their potential to heal trauma, PTSD, depression, anxiety, and a range of other mood and mental health challenges. In functional medicine, where we seek root-cause solutions and personalized care, psychedelics offer a promising avenue to address the underlying neurobiological and emotional drivers of these conditions. Let’s explore how these compounds are being tested, implemented, and understood—both globally and in Australia—along with their mechanisms, successes, and potential pitfalls, supported by key references.

The Psychedelic Renaissance: Where They’re Being Tested

The resurgence of psychedelic research has gained momentum worldwide, with clinical trials and real-world applications breaking new ground. Ketamine, a dissociative anesthetic, has been a trailblazer. Frequently used on children and adults as a short acting surgical anaesthetic, it has a long history of safety when used appropriately. In the United States, the FDA approved esketamine (a ketamine derivative) as a nasal spray called Spravato in 2019 for treatment-resistant depression (FDA, 2019). Clinics and hospitals across the globe perform ketamine infusions off-label for depression, anxiety, PTSD, and chronic pain, with studies showing rapid symptom relief—often within hours—compared to weeks for traditional antidepressants. For example, a 2021 study in The American Journal of Psychiatry found that ketamine reduced suicidal ideation in depressed patients within 24 hours, a critical intervention for acute crises (Wilkinson et al., 2021).

MDMA, known recreationally as ecstasy, has shown extraordinary promise for PTSD. The Multidisciplinary Association for Psychedelic Studies (MAPS) in the U.S. completed Phase 3 trials in 2021, reporting that 67% of participants with severe PTSD no longer met diagnostic criteria after three MDMA-assisted therapy sessions (Mitchell et al., 2021). This led to an FDA Breakthrough Therapy Designation, fast-tracking its path to potential approval. In Australia, the TGA made history in 2023 by reclassifying MDMA as a Schedule 8 controlled medicine, allowing authorized psychiatrists to prescribe it for PTSD starting July 1, 2023—making Australia the first country to legalize it for therapeutic use (TGA, 2023).

Psilocybin, the active compound in magic mushrooms, is gaining traction for depression and anxiety, particularly in end-of-life care. A landmark 2016 study at Johns Hopkins University found that a single high dose of psilocybin reduced depression and anxiety in 80% of cancer patients, with effects lasting six months or more (Griffiths et al., 2016). In Australia, the TGA also approved psilocybin for treatment-resistant depression in 2023, alongside MDMA, following trials like those at St Vincent’s Hospital in Melbourne, where researchers are exploring its efficacy in palliative care settings (TGA, 2023; St Vincent’s Hospital Melbourne, ongoing).

DMT (N,N-Dimethyltryptamine), a short-acting but intense psychedelic found in ayahuasca, is less studied but showing early potential. Small Pharma, a UK biotech, launched the world’s first clinical trial of DMT-assisted therapy for depression in 2021, combining it with psychotherapy (Small Pharma, 2021). Preclinical rodent studies from 2019 in ACS Chemical Neuroscience suggest DMT reduces anxiety and depressive behaviors by enhancing fear extinction—a key factor in trauma recovery (Cameron et al., 2019). In Australia, while DMT remains a Schedule 9 prohibited substance, interest is growing, with researchers at Monash University exploring its neuroplastic effects in preclinical models (Monash University, ongoing).

Beyond Mood Disorders: Broader Applications

Psychedelics are also being investigated for conditions beyond the usual suspects. Ketamine shows promise for substance use disorders, with a 2022 trial in The American Journal of Psychiatry demonstrating reduced alcohol relapse rates when paired with therapy (Grabski et al., 2022). MDMA is under study for social anxiety in autism, with a 2018 pilot study reporting improved emotional connection after two sessions (Danforth et al., 2018). Psilocybin is being tested for obsessive-compulsive disorder (OCD) and cluster headaches, with a 2023 Yale study noting significant OCD symptom reduction (Kelmendi et al., 2023). DMT’s potential extends to stroke recovery, with preclinical research hinting at neuroregenerative effects (Nardai et al., 2020). These applications highlight psychedelics’ versatility in addressing both mental and neurological challenges.

Why They Work: The Science of Psychedelic Healing

Psychedelics’ effectiveness stems from their ability to reshape brain function and emotional processing. Ketamine acts on glutamate receptors (NMDA), boosting neuroplasticity—the brain’s ability to form new connections. This “reset” of neural circuits can disrupt the rigid thought patterns of depression or PTSD, offering rapid relief (Zanos & Gould, 2018). Its dissociative effects also allow patients to view trauma from a detached perspective, facilitating therapeutic breakthroughs.

MDMA enhances serotonin, dopamine, and oxytocin release, creating a state of emotional openness and reduced fear. This makes it ideal for PTSD, as it helps patients revisit traumatic memories without overwhelming distress, fostering trust with therapists. A 2021 Nature Medicine study suggests MDMA dampens amygdala activity (the brain’s fear center), enabling emotional processing that traditional therapy alone often can’t achieve (Mitchell et al., 2021).

Psilocybin binds to serotonin 5-HT2A receptors, increasing connectivity between brain regions that don’t typically communicate—like the default mode network (DMN), which governs self-referential thinking. A 2022 Nature study found that psilocybin quiets the DMN, reducing rumination in depression and promoting a sense of unity or “ego dissolution,” often described as spiritually transformative (Daws et al., 2022).

DMT shares psilocybin’s serotonin agonism but acts faster and more intensely. Its ability to induce vivid, dream-like states may accelerate fear extinction and emotional insight, though its brevity (effects last 5–20 minutes) requires precise therapeutic integration. Research suggests it promotes neurogenesis, potentially repairing trauma-damaged neural pathways (Cameron et al., 2019).

Negative Findings and Caveats

Despite their promise, psychedelics aren’t without risks. Ketamine can cause transient increases in blood pressure and dissociation, posing risks for those with heart conditions or psychotic tendencies (Wilkinson et al., 2021). Long-term recreational use is linked to bladder damage, though therapeutic doses are lower and supervised (Shahani et al., 2007). MDMA carries risks of overheating or serotonin syndrome if misused, and a 2024 FDA advisory panel raised concerns about trial biases and potential abuse, delaying U.S. approval (FDA, 2024). Psilocybin may trigger anxiety or paranoia during sessions, especially in uncontrolled settings, and a 2023 meta-analysis in BMJ cautioned that its efficacy for depression needs larger, more diverse studies (Goodwin et al., 2023). DMT’s intensity can be overwhelming, with limited data on long-term effects raising questions about safety (Barker, 2018).

In Australia, implementation has faced hurdles. High costs—MDMA or psilocybin therapy can exceed $10,000 AUD per course—limit access, and the TGA’s strict psychiatrist-only prescribing rules exclude many rural patients (TGA, 2023). Reports from X posts in 2023 noted public frustration over slow rollout and concerns about inequity, echoing global debates on scalability.

A Functional Medicine Perspective: The Path Forward

At our functional medicine practice, we see psychedelics as part of a holistic toolkit—complementing nutrition, lifestyle, and personalised care. Their ability to address root causes like trauma or chronic stress aligns with our mission. Australia’s pioneering legalization offers a model, but education and integration are key. If you’re intrigued by these therapies, consult a qualified practitioner to explore their fit for your journey. As of March 10, 2025, the evidence is mounting: psychedelics could redefine mental health care—but only if we balance innovation with caution.

References

Barker, S. A. (2018). N,N-Dimethyltryptamine (DMT), an endogenous hallucinogen: Past, present, and future. Frontiers in Neuroscience, 12, 536.
Cameron, L. P., et al. (2019). Effects of N,N-Dimethyltryptamine on rat behaviors relevant to anxiety and depression. ACS Chemical Neuroscience, 10(3), 1582–1590.
Danforth, A. L., et al. (2018). MDMA-assisted therapy for social anxiety in autistic adults: A pilot study. Psychopharmacology, 235(9), 2561–2571.
Daws, R. E., et al. (2022). Increased global integration in the brain after psilocybin therapy for depression. Nature, 13, 1–9.
FDA. (2019). FDA approves Spravato (esketamine) for treatment-resistant depression. FDA News Release.
FDA. (2024). Advisory committee meeting on MDMA-assisted therapy: Summary of findings.
Goodwin, G. M., et al. (2023). Psilocybin for treatment-resistant depression: A systematic review and meta-analysis. BMJ, 382, e074068.
Grabski, M., et al. (2022). Ketamine-assisted psychotherapy for alcohol use disorder: A randomized controlled trial. The American Journal of Psychiatry, 179(1), 61–70.
Griffiths, R. R., et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. Journal of Psychopharmacology, 30(12), 1181–1197.
Kelmendi, B., et al. (2023). Psilocybin-assisted therapy for obsessive-compulsive disorder: Preliminary findings. Yale Journal of Psychiatry.
Mitchell, J. M., et al. (2021). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025–1033.
Nardai, S., et al. (2020). DMT’s potential neuroprotective effects in stroke models. Brain Research Bulletin, 162, 232–239.
Shahani, R., et al. (2007). Ketamine-associated ulcerative cystitis: A new clinical entity. Urology, 69(5), 810–812.
Small Pharma. (2021). World’s first clinical trial of DMT-assisted therapy for depression. Press Release.
TGA. (2023). Reclassification of MDMA and psilocybin as Schedule 8 medicines for therapeutic use. Therapeutic Goods Administration Announcement.
Wilkinson, S. T., et al. (2021). A single dose of ketamine reduces suicidal ideation in treatment-resistant depression. The American Journal of Psychiatry, 178(5), 428–436.
Zanos, P., & Gould, T. D. (2018). Mechanisms of ketamine action as an antidepressant. Molecular Psychiatry, 23(4), 801–811.

Disclaimer: Psychedelics remain controlled substances in many regions, including Australia outside approved contexts. Always seek professional medical advice before considering these treatments.

Back to blog

Item added to your cart